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Abstract 
BACKGROUND: Cutaneous B-cell lymphomas represent about 25% of all cutaneous lymphomas. Peripheral 
diffuse large B-cell lymphoma of the leg type is the most aggressive subtype seen mainly in elderly patients. 
Treatment is not standardised. 
CASE REPORT: An 87-year-old female patient was presented in May 2018 because of the development of 
painless subcutaneous nodules on the legs since late 2017. On examination, we observed up to 5 cm large 
erythematous nodules on the legs and a smaller plaque in the left submammary fold. The histology of a skin 
demonstrated tumour infiltrate that was separated from the overlying epidermis by a grenz zone. It consisted of 
densely packed, blastoid lymphocytic cells with numerous, and some atypical mitoses. The cells were positive for 
CD20, CD79A and CD5. Almost 100% of the cells were labelled with Ki67. The diagnosis of a diffuse large B-cell 
lymphoma (PCLBCL-LT) of the leg was confirmed. Histologic analysis of a bone marrow biopsy demonstrated a 
hypercellular bone marrow without malignant lymphatic infiltrates. Diagnostic ultrasound of cervical nodes and 
computerised tomography (CT) scans (native and with contrast medium) of head, neck and trunk excluded an 
extracutaneous manifestation of the PCLBCL-LT. Treatment with rituximab plus bendamustibe was initiated, but 
tumour progress was noted after the second course. Suggested palliative therapy with radiation and rituximab 
was refused. The patient died 7 months after diagnosis. 
CONCLUSIONS: Although some trials suggested a beneficial effect of immuno-chemotherapy, the prognosis 
of (PCLBCL-LT) remains poor. Standardised treatment is missing due to the relative rarity of this malignancy. 
 
 
 
 
 
 
Introduction 
 
Among all primary cutaneous lymphomas, B-
cell lymphomas (CBCL) represent the minority with 
25% of all cases. Their diagnosis is based on 
histopathology, immunohistochemistry, and staging 
evaluation. There are 3 types of primary (CBCL): 
primary cutaneous marginal zone lymphoma, primary 
cutaneous follicle centre lymphoma, and primary 
cutaneous diffuse large B-cell lymphoma, leg-type and 
NOS-type (not otherwise specified) [1]. Since these 
malignancies have the same morphology as their 
systemic counterparts, the diagnosis is one of 
exclusion of extracutaneous manifestation. 
Cutaneous large B-cell lymphomas that 
contain a majority (≥ 80%) of large-cells and a 
proliferative rate ≥ 40% need further subtyping into 
diagnosis between leg type peripheral B-cell 
lymphoma (PCLBCL-LT) or primary cutaneous follicle 
centre lymphoma with large cell morphology (PCFCL-
LC), and unclassified lymphomas (PCLBCL/NOS). 
Both CD10 and MUM1 are characteristic for the leg-
type [2]. Patients with PCLBCLs-LT are on average 
older than those with (PCLBCL/NOS) and express 
more Bcl-2. Negative prognostic markers are Bcl-2, 
MYC rearrangements, and female gender, while 
proliferation rate (Ki67) is not of prognostic 
significance. Overall survival (OS) is poorer for 
PCLBCL-LT than PCFCL-LC or PCLBCL/NOS [2], [3], 
[4]. 
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Case Report 
 
An 87-year-old female patient presented in 
May 2018 because of the development of painless 
subcutaneous nodules on the legs since late 2017. 
Past medical history was positive for a basal cell 
carcinoma of the nose which had been surgically 
removed in 2016, bilateral knee replacement and a 
large goitre. 
On examination, we observed up to 5 cm 
large erythematous nodules on the legs and a smaller 
plaque in the left submammary fold (Figure 1).  
 
Figure 1: Primary cutaneous diffuse large B-cell lymphoma, leg-
type; A) Large tumour nodules of the legs; B) Tumor plaque of the 
left submammary fold 
 
A skin biopsy was performed. The tumour 
infiltrates separated from the overlying epidermis by a 
grenz zone. It consisted of densely packed, blastoid 
lymphocytic cells with numerous, and some atypical 
mitoses (Figure 2).  
 
Figure 2: Histopathology of primary cutaneous diffuse large B-cell 
lymphoma, leg-type, with a grenz zone and blastoid lymphocytic 
cells of the dermis (Hematoxylin-eosin x 2) 
 
The cells were positive for CD20, CD79A and 
CD5. Almost 100% of the cells were labelled with Ki67 
(Figure 3). There was no reactivity with antibodies 
against CD10, CD30, Bcl-2, Bcl-6, cylin D1 and 
SOX11. The diagnosis of a diffuse large B-cell 
lymphoma (PCLBCL-LT) of the leg was confirmed.  
 
Figure 3: Immunohistology of primary cutaneous diffuse large B-cell 
lymphoma, leg-type, peroxidase stain; A) CD20 (x 10); B) Ki67 (x 
10) 
 
Histologic analysis of a bone marrow biopsy 
demonstrated a hypercellular bone marrow without 
malignant lymphatic infiltrates. Diagnostic ultrasound 
of cervical nodes and computerised tomography (CT) 
scans (native and with contrast medium) of head, 
neck and trunk demonstrated the giant goitre but no 
hints of an extracutaneous manifestation of the 
PCLBCL-LT were found. Laboratory investigations: 
Initially, we observed a leucopenia of 3.29 Gpt/L 
(Normal range: 3.8-11.0), increased lactate 
dehydrogenase of 5.33 µkat/L (2.25-3.55), beta-2-
microglobulin 3.3 mg/L (0.8-2.4), and strongly 
increased soluble interleukin-2 receptor of 1,188 U/mL 
(223-710). In the differential blood count, there was a 
lymphopenia of 8%. 
She was presented to the interdisciplinary 
tumour board. Combination of rituximab / 
bendamustin therapy was initiated, and adjuvant 
neutropenia prophylaxis with granulocyte-colony 
stimulation factor (Neupogen) was administered. 
Infection prophylaxis with trimethoprim – 
sulfamethoxazole, and substitution with folic acid and 
vitamin B12 completed the medical treatment. She 
has undergone two cycles but experienced progress 
of the disease after an initial partial response. 
Therefore, palliative radiotherapy, in combination with 
rituximab once a week was planned. Tumour nodules 
increased by size and by number, the larger ones 
exulcerated. The patients rejected the suggested 
palliative treatment. She died 7 months after 
confirmation of the diagnosis. 
 
 
Discussion 
 
PCLBCL-LT is clinically more aggressive than 
other primary cutaneous B-cell lymphomas. This 
malignancy usually affects elderly females (mean age 
76 years) and presents with rapidly progressive 
tumour nodules of the lower legs. The treatment is 
more challenging since PCLBCL-LT usually require 
multi-agent chemotherapy (cyclophosphamide, 
doxorubicin or epirubicin, vincristine, prednisone) and 
anti-CD20 monoclonal antibodies as their systemic 
counterparts [5], [6]. Most patients present with 
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disease confined to the leg(s). Although only a few 
reports are available, the use of R‐CHOP (with anti-
CD20 monoclonal antibody rituximab) in these 
patients is associated with disease‐free survival rates 
comparing to those of patients with high‐risk systemic 
diffuse large B-cell lymphomas. Field radiation therapy 
is another option. The overall 5-year disease-specific 
survival rate has been estimated as 41%-50%. 
Location on the leg and multiple skin lesions were 
predictive of death in multivariate analysis [7], [8]. In 
another trial, disease-specific survival at 5 years was 
100% for those receiving rituximab versus 67% for no 
rituximab [9]. Rituximab plus bendamustine is 
effective in a variety of lymphomas, including relapsed 
or refractory diffuse large B cell lymphoma [10], [11], 
[12]. One study in aggressive diffuse B-cell lymphoma 
achieved an objective response rate of 45.8 % 
(complete response, 15.3%; partial response, 30.5%). 
The median duration of response was 17.3 months, 
and the median progression-free survival lasted 3.6 
months [11]. 
PCLBCL-LT is an aggressive variant of 
primary cutaneous B-cell lymphomas. Our patient 
belonged to the typical age group. Negative 
prognostic markers are female gender, Bcl-2 
expression, and MYC rearrangements [2], [3], [4]. We 
did not perform an MYC rearrangement analysis. Her 
lymphoma did not express Bcl-2. Weekly immuno-
chemotherapy with rituximab and alkylating agent 
bendamustine was initiated. After an initial partial 
response, the situation worsened in our patient. 
Therefore, the combination was stopped after the 
second cycle. Recently, Bruton’s tyrosine kinase 
inhibitor ibrutinib combined with chemotherapy-
induced a durable remission in PCLBCL-LT with 
mutant MYD88 and wild type CD79 [13]. A single-arm 
phase II trial with the thalidomide derivate 
lenalidomide in relapsing or refractory PCLBCL-LT 
achieved a response rate of 26.3% with 4 complete 
responses. The median overall survival was 19.4 
months [14].  
Although another palliative approach had 
been suggested, the patient rejected any further 
therapy and died seven months after confirmation of 
the diagnosis. More effective treatment options that 
are tolerable in elderly patients are needed to improve 
prognosis. 
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